Fosun Pharma (Group) Co., Ltd. (hereinafter referred to as "Fosun Pharma") issued a joint announcement on July 15, 2024, announcing the delay in the issuance of comprehensive documents regarding the privatization proposal of its subsidiary Shanghai Henlius Biotech, Inc. (stock code: 02696). The privatization proposal involves the privatization of Henlius by way of absorption and merger by Fosun Pharma Research Co., Ltd. and proposes the cancellation of Henlius's listing status. According to the regulations of the acquisition, the comprehensive documents were originally scheduled to be sent within 21 days after the joint announcement on June 24, 2024, but due to the fact that the preconditions for the merger have not been met, including the need to obtain the approval of relevant government departments such as...Show More

Fosun Pharma (Group) Co., Ltd. (hereinafter referred to as "Fosun Pharma") issued a joint announcement on July 15, 2024, announcing the delay in the issuance of comprehensive documents regarding the privatization proposal of its subsidiary Shanghai Henlius Biotech, Inc. (stock code: 02696). The privatization proposal involves the privatization of Henlius by way of absorption and merger by Fosun Pharma Research Co., Ltd. and proposes the cancellation of Henlius's listing status. According to the regulations of the acquisition, the comprehensive documents were originally scheduled to be sent within 21 days after the joint announcement on June 24, 2024, but due to the fact that the preconditions for the merger have not been met, including the need to obtain the approval of relevant government departments such as the National Development and Reform Commission and the Ministry of Commerce of China, the company has applied for a postponement within 7 days after the preconditions are met or on May 7, 2025. Fosun Pharma emphasized that the effectiveness of the merger agreement is still a possibility and reminds shareholders and potential investors to act cautiously when trading securities.